| Range: | 26.38-59.754 | Vol Avg: | 640540 | Last Div: | 0 | Changes: | 3.15 |
| Beta: | -1.44 | Cap: | 2.49B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Nov 13 2014 | Empoloyees: | 33 | ||
| CUSIP: | 834203200 | CIK: | 0001484565 | ISIN: | US8342033094 | Country: | US |
| CEO: | Dr. Anish Bhatnagar M.D. | Website: | https://soleno.life | ||||
SLNO 59.59 Stock Price Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Stock Details
Positive 0.33
Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments
Soleno Therapeutics' DCCR shows promising results in reducing hyperphagia in PWS patients....
seekingalpha.com·Thu Oct 10 2024
Positive 0.45
SLNO Stock Rises as Prader-Willi Treatment Nears FDA Approval
Soleno Therapeutics (SLNO, Financial) experienced a notable stock price increase of 9.11% ...
gurufocus.com·Tue Oct 08 2024
Positive 0.59
Why Soleno Therapeutics Stock Blasted 9% Higher Today
The company's Prader-Willi treatment inched closer to FDA approval....
fool.com·Tue Oct 08 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow